NCT03924895 · MORE INFO

Limitations, agreements, and source contact

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) · Source last updated 2026-06-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialsDisclosure@msd.com
organization: Merck Sharp & Dohme LLC
phone: 1-800-672-6372
title: Senior Vice President, Global Clinical Development

Complete source fields

certain Agreement

other Details: If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialsDisclosure@msd.com
organization: Merck Sharp & Dohme LLC
phone: 1-800-672-6372
title: Senior Vice President, Global Clinical Development

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice